Liraglutide cardioprotective in high-risk Type 2 diabetes patients
Findings of the LEADER trial show that liraglutide treatment may confer a reduced risk of cardiovascular events in patients with Type 2 diabetes and a high vascular risk.
Source: MedWire News - Category: Consumer Health News Tags: Diabetes Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Health | Heart | Victoza